Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03577743|
Recruitment Status : Recruiting
First Posted : July 5, 2018
Last Update Posted : May 19, 2020
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Triple Negative Breast Cancer Safety Issues Efficacy||Drug: Bevacizumab||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer|
|Actual Study Start Date :||July 1, 2018|
|Estimated Primary Completion Date :||May 2020|
|Estimated Study Completion Date :||September 2021|
Experimental: experimental arm
bevacizumab and chemotherapy given every 21 day untill disease progression or unacceptable toxicity
-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
Other Name: avastin
- - progression free survival [ Time Frame: after six month from last enrollment ]the length of time during and after the treatment that a patient lives with the disease but it does not get worse
- - Response rate (R.R) : [ Time Frame: after 1 year from enrollment ]length of time from the date of diagnosis to the time of death or lost follow up.
- - Over all survival. [ Time Frame: after 3 years ]the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03577743
|Contact: Hebat-Allah M BAKRI, firstname.lastname@example.org|
|Contact: SAMIR S EID, email@example.com|
|Study Director:||assuit university||Assiut University|